Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AKRN Scientific Consulting, S.L. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
A prospective, multi-center study with the CathVision Cube® system and the PVI Analyzer software in radiofrequency (RF), cryo-balloon (CB), and Pulse Field Ablation (PFA) procedures.
Subjects with paroxysmal or persistent atrial fibrillation (AF) who are indicated to undergo first pulmonary vein isolation (PVI) procedure and meet all eligibility criteria will be enrolled in the Study. Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the conventional (CE marked) EP recording system. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the automated algorithm for PVI will be performed offline
The primary objective is to validate the PVI Analyzer software with a novel EP recording system (CathVision Cube® System) for assisting assessment of isolation status following PVI ablation.
The secondary objective is to determine the feasibility of "real-time" assessment of PVI analysis and rhythm dependent performance using the PVI Analyzer and CathVision Cube® System.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Group | Experimental | Index EP Procedure: Ablation of atrial fibrillation |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CathVision Cube® system | Device | Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively. |
| Measure | Description | Time Frame |
|---|---|---|
| PVI Analyzer Sensitivity and Specificity, Measured as the Accuracy of Predictions for Non-isolated and Isolated Veins. | The primary outcome is to evaluate the sensitivity and specificity of the PVI Analyzer in the classification of the isolation status of veins, following the medical procedure known as pulmonary vein isolation (PVI). The information used for this has been obtained from the investigational CathVision Cube System. The PVI Analyzer determines whether the veins are isolated or not after pulmonary vein ablation. The proportion of correct negative (non-isolated) predictions among non-isolated vein data points and the proportion of correct positive (isolated) data points from isolated veins, provide the sensitivity and specificity data, respectively. | From EP procedure until study completion at discharge; an average of 24 hours. |
| PVI Analyzer Safety Profile, Measured as the Number of Adverse Events and/or Device Malfunctions. | As part of the primary outcome, safety is also evaluated as the number of adverse events and device malfunctions reported by the study team at site, during the use of the CathVision Cube® System from the start of the procedure until discharge. The number of adverse events and device malfunctions is recorded in the site's source documents as well as in the case report form (CRF) and is duly informed to the Sponsor who also keeps the record. | From EP procedure until study completion at discharge; an average of 24 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| The Pulmonar Vein Isolation (PVI) Classification in Sinus Rhythm (SR) Considering the Electrophysiology Procedure Type. | This outcome assesses the overall classification of pulmonary vein isolation (PVI) in sinus rhythm (SR) based on the type of electrophysiology procedure performed. The classification provides insights into the accuracy of the procedure in achieving SR. The overall classification was evaluated in terms of sensitivity and specificity. To calculate specificity from the total number of EGMS analyzed, all the correct negatives (non-isolated) / Correct negatives + False positives were considered. To calculate sensitivity, all the correct positives (isolated) / Correct positives + False negatives were considered. As the sample size was not adjusted to detect the differences for variables other than the primary endpoint, the p-values obtained from the analyses of secondary outcomes should be viewed as complementary to the primary outcome results. Their primary purpose was to generate hypotheses rather than draw definitive conclusions. |
Not provided
Eligible subjects will meet all of the following inclusion criteria:
Eligible subjects will not meet any of the following exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mattias Duytschaever, Prof. MD PhD | AZ Sint-Jan Hospital, Ruddershove 10 8000 Brugge, Belgium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AZ Sint-Jan Hospital | Bruges | 8000 | Belgium | |||
| Universitair Ziekenhuis Brussel |
Not provided
Not provided
Not provided
Not provided
Not provided
Three of the subjects were considered screening failures since not all eligibility criteria were met, and the subjects were excluded from the study. Out of the 101 subjects enrolled, 4 subjects were excluded from the Per-Protocol Treatment analysis, as minimum required measurements could not be taken. Therefore, the final PPT population for analysis was 97 subjects.
The enrollment took place between September 15, 2021 and June 22, 2022 at four sites (hospitals) located in Bruges, Brussels, Ghent and Toulouse. At these hospitals, participants were assessed for eligibility to participate in the clinical investigation, and those who met the eligibility criteria, voluntarily gave their informed consent. Those who were successfully enrolled were monitored until their hospital discharge, and no further follow-up was deemed necessary.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Index EP Procedure: Ablation of Atrial Fibrillation | This is a single arm study that is assigned to subjects undergoing first-time pulmonary vein isolation indicated by investigator for the treatment of atrial fibrillation. Subjects were distributed in two different procedures (RF and cryo-balloon) according to medical decision and standard of care practice at the study sites. At a later stage, a protocol amendment planned an additional enrolment undergoing the standard of care PFA procedure Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Index EP Procedure: Ablation of Atrial Fibrillation | CathVision Cube® system: Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | PVI Analyzer Sensitivity and Specificity, Measured as the Accuracy of Predictions for Non-isolated and Isolated Veins. | The primary outcome is to evaluate the sensitivity and specificity of the PVI Analyzer in the classification of the isolation status of veins, following the medical procedure known as pulmonary vein isolation (PVI). The information used for this has been obtained from the investigational CathVision Cube System. The PVI Analyzer determines whether the veins are isolated or not after pulmonary vein ablation. The proportion of correct negative (non-isolated) predictions among non-isolated vein data points and the proportion of correct positive (isolated) data points from isolated veins, provide the sensitivity and specificity data, respectively. | The performance assessment was done in the PPT population, with a total of 85 subjects. Subjects undergoing PFA were excluded from this analysis despite being included in the PPT population, since the primary endpoint was specific to RF and Cryo procedures only. Up to 248 EGMs were recorded at 'T-baseline' (prior to isolation) and labeled as ground-truth negative (non-isolated); and 250 EGMs were recorded at 'T-final' (after isolation) and labeled as ground-truth positive (isolated). | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
Adverse events data were collected from participants' electrophysiology procedure until study completion at discharge (hospitalization time approximately 1-2 days).
The assessment of the PVI Analyzer software analysis was performed offline and retrospectively, the AEs related to the device and device malfunctions reported were expected to be minimal or even absent. Determination of whether the investigational product contributed to an AE is to be determined by the Investigator. All efforts were made by the investigator to remain alert to possible AEs.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Adult Patients With Cardiac Arrhythmia Undergoing Cryoballoon | Safety was evaluated in adult patients diagnosed with cardiac arrhythmia, including patients with supraventricular tachycardia and ventricular tachycardia undergoing Cryoballoon procedure |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Prolongation of an existing hospitalization | Surgical and medical procedures | Non-systematic Assessment | Related to the standard of care procedure. Due to a prolongation of hospitalization, this event was considered as Serious Adverse Event. |
Not provided
Only a limited amount of data (30 seconds) could be exported from the LS Pro system, which limited the correlation to only search a narrow region around the exported EGM data.
The data obtained from the PFA procedures could not be assessed due to incompatibility with the PVI Analyzer algorithm.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mads Matthiesen | CathVision | +4531470730 | mem@cathvision.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 20, 2021 | Jan 30, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 30, 2022 | Jan 30, 2024 | SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | May 20, 2021 | Jan 30, 2024 | ICF_002.pdf |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From EP procedure until study completion at discharge; an average of 24 hours. |
| Feasibility of "Real-time" Assessment of Isolation, Measured by Retesting the Accuracy of the PVI Analyzer Classification of Isolation Status at Different Timepoints Before, During and After Ablation. | The device's feasibility was evaluated by reassessing its accuracy. It refers to the consistency in the re-classification of pairs of non-overlapping samples throughout the different timepoints of ablation-prior to, during, and following the procedure. For this evaluation, the same EGMs of the primary endpoint were used, including only EGMs from T Baseline and T Final measurements from patients in sinus rhythm. The extraction of non-overlapping samples was selected by considering only those EGMs with a number of global isolation index values above 6. The global isolation index value is an indicator from the PVI analyzer that is used to assess the overall effectiveness of the ablation in isolating specific regions of the heart. The fourth and last global index returned by the PVI Analyzer were used as pairs for analyzing the outcome. The accuracy was calculated as the percentage of EGMs with agreement across timepoints with respect to the total number of EGMs performed. | From EP procedure until study completion at discharge; an average of 24 hours. |
| PVI Isolation Classification in Non-sinus Rhythm (NSR) From EP Procedure | The PVI isolation classification in non-sinus rhythm (NSR) from EP procedure was focused on the analysis of all EGM in non-sinus rhythm. The data analysis and processing were similar to those of the primary endpoint, but taking into consideration that subjects shall be in non-sinus rhythm during the duration of the EGM snippet. Apart from this, the processing was the same and the threshold was also defined as 50: values below 50 were classified as baseline, while values at or above 50 were considered as isolated veins. | From EP procedure until study completion at discharge; an average of 24 hours. |
| Accuracy of PVI Analyzer Classification at the Time of Expert-defined Isolation | This secondary endpoint aimed to determine the sensitivity of the PVI Analyzer at the time of isolation, which requires the EGMs at the T PVI. The T PVI EGMs were extracted by taking EGM snippets of 4 seconds around the T PVI event. All of those EGMs were expected to be from isolated veins (ground-truth is isolated). Then, they were processed by the PVI Analyzer, and the last valid global isolation index output was used for endpoint assessment. | From EP procedure until study completion at discharge; an average of 24 hours. |
| Comparison of the PVI Analyzer Performance With CathVision Cube® System Data With Its Performance With Data From Other Conventional EP Systems Used | The conventional EP system and CathVision Cube® System were running on two different PCs in the EP laboratory in parallel. The relevant EGM snippets were extracted from the conventional EP system using a time offset between the conventional EP system PC and the Cube PC. Since a very similar number of samples were used to compute the results, no statistical assessment of the sampling variation in the sensitivity and specificity was made. A paired McNemars test, with an alpha value of 0.05, was applied to analyze the differences in classification performance. | From EP procedure until study completion at discharge; an average of 24 hours. |
| Brussels |
| 1090 |
| Belgium |
| Ghent University Hospital | Ghent | 9000 | Belgium |
| Clinique Pasteur Toulouse, | Toulouse | 31300 | France |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Height [cm] | Mean | Standard Deviation | cm |
|
| Weight [kg] | Mean | Standard Deviation | kg |
|
| Systolic Blood Pressure [mmHg] | Mean | Standard Deviation | mmHg |
|
| Diastolic Blood Pressure [mmHg] | Mean | Standard Deviation | mmHg |
|
| Heart Rate [BPM] | Mean | Standard Deviation | BPM |
|
| Respiratory Rate [breaths/min] | Mean | Standard Deviation | breaths/min |
|
| Body Temperature [°C] | Mean | Standard Deviation | ºC |
|
|
|
|
|
| Primary | PVI Analyzer Safety Profile, Measured as the Number of Adverse Events and/or Device Malfunctions. | As part of the primary outcome, safety is also evaluated as the number of adverse events and device malfunctions reported by the study team at site, during the use of the CathVision Cube® System from the start of the procedure until discharge. The number of adverse events and device malfunctions is recorded in the site's source documents as well as in the case report form (CRF) and is duly informed to the Sponsor who also keeps the record. | All enrolled subjects. | Posted | Number | participants | From EP procedure until study completion at discharge; an average of 24 hours. |
|
|
|
|
| Secondary | The Pulmonar Vein Isolation (PVI) Classification in Sinus Rhythm (SR) Considering the Electrophysiology Procedure Type. | This outcome assesses the overall classification of pulmonary vein isolation (PVI) in sinus rhythm (SR) based on the type of electrophysiology procedure performed. The classification provides insights into the accuracy of the procedure in achieving SR. The overall classification was evaluated in terms of sensitivity and specificity. To calculate specificity from the total number of EGMS analyzed, all the correct negatives (non-isolated) / Correct negatives + False positives were considered. To calculate sensitivity, all the correct positives (isolated) / Correct positives + False negatives were considered. As the sample size was not adjusted to detect the differences for variables other than the primary endpoint, the p-values obtained from the analyses of secondary outcomes should be viewed as complementary to the primary outcome results. Their primary purpose was to generate hypotheses rather than draw definitive conclusions. | This secondary outcome assessed the overall classification accuracy of the PVI Analyzer in sinus rhythm (SR) computing the results only in radiofrequency and cryoballoon procedures. Therefore, the dataset used for the analysis is the same as for the primary endpoint (85), but subgrouping the data by the type of procedure. | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
|
|
|
|
| Secondary | Feasibility of "Real-time" Assessment of Isolation, Measured by Retesting the Accuracy of the PVI Analyzer Classification of Isolation Status at Different Timepoints Before, During and After Ablation. | The device's feasibility was evaluated by reassessing its accuracy. It refers to the consistency in the re-classification of pairs of non-overlapping samples throughout the different timepoints of ablation-prior to, during, and following the procedure. For this evaluation, the same EGMs of the primary endpoint were used, including only EGMs from T Baseline and T Final measurements from patients in sinus rhythm. The extraction of non-overlapping samples was selected by considering only those EGMs with a number of global isolation index values above 6. The global isolation index value is an indicator from the PVI analyzer that is used to assess the overall effectiveness of the ablation in isolating specific regions of the heart. The fourth and last global index returned by the PVI Analyzer were used as pairs for analyzing the outcome. The accuracy was calculated as the percentage of EGMs with agreement across timepoints with respect to the total number of EGMs performed. | EGMs with a number of global isolation index values above 6 were selected. For those EGMs, the fourth and last global index returned by the PVI Analyzer were used. This value was compared at different time points of the procedure, to confirm whether there was an ECG agreement or not. The number of EGM with agreement was 475/495, and the number of EGM without agreement was 20/475. | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
|
|
|
|
| Secondary | PVI Isolation Classification in Non-sinus Rhythm (NSR) From EP Procedure | The PVI isolation classification in non-sinus rhythm (NSR) from EP procedure was focused on the analysis of all EGM in non-sinus rhythm. The data analysis and processing were similar to those of the primary endpoint, but taking into consideration that subjects shall be in non-sinus rhythm during the duration of the EGM snippet. Apart from this, the processing was the same and the threshold was also defined as 50: values below 50 were classified as baseline, while values at or above 50 were considered as isolated veins. | The performance assessment was done in the Per Protocol (PPT) population, with a total of 85 participants. The PVI isolation classification in non-sinus rhythm (NSR) from EP procedure was focused on the analysis of all EGM in non-sinus rhythm which in this case were 55 in T-baseline and 44 in T-final, a total of 99 ECGs. However, the system rejected 9 ECGs in T-baseline and 3 in T-final, therefore, the ECGs used for this secondary outcome were 46 in T-baseline and 41 in T-final. | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
|
|
|
|
| Secondary | Accuracy of PVI Analyzer Classification at the Time of Expert-defined Isolation | This secondary endpoint aimed to determine the sensitivity of the PVI Analyzer at the time of isolation, which requires the EGMs at the T PVI. The T PVI EGMs were extracted by taking EGM snippets of 4 seconds around the T PVI event. All of those EGMs were expected to be from isolated veins (ground-truth is isolated). Then, they were processed by the PVI Analyzer, and the last valid global isolation index output was used for endpoint assessment. | In many cases, the actual isolation time was not directly observable, and the investigator was only asked to annotate T PVI if it was observed. During RF procedures, T PVI can be difficult to observe and during cryo-balloon application, freeze noise from the cryoballoon can make identification of T PVI difficult. The annotation the EGMs at the T PVI was not always possible and only 116 valid EGMs at T PVI were collected. During processing, 17 EGMs were rejected by the PVI Analyzer. | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
|
|
|
|
| Secondary | Comparison of the PVI Analyzer Performance With CathVision Cube® System Data With Its Performance With Data From Other Conventional EP Systems Used | The conventional EP system and CathVision Cube® System were running on two different PCs in the EP laboratory in parallel. The relevant EGM snippets were extracted from the conventional EP system using a time offset between the conventional EP system PC and the Cube PC. Since a very similar number of samples were used to compute the results, no statistical assessment of the sampling variation in the sensitivity and specificity was made. A paired McNemars test, with an alpha value of 0.05, was applied to analyze the differences in classification performance. | It was not possible to extract all EGM snippets from the conventional systems, as all data from Toulouse was not available. Due to technical reasons and time constraints, only the first 12 patients from Ghent were included in the analysis. | Posted | Count of Units | Electrogram (EGM) | From EP procedure until study completion at discharge; an average of 24 hours. | Electrogram (EGM) | Electrogram (EGM) |
|
|
|
|
| 0 |
| 47 |
| 0 |
| 47 |
| 0 |
| 47 |
| EG001 | Adult Patients With Cardiac Arrhythmia Undergoing Radiofrequency | Safety was evaluated in adult patients diagnosed with cardiac arrhythmia, including patients with supraventricular tachycardia and ventricular tachycardia undergoing Radiofrequency procedure | 0 | 42 | 1 | 42 | 0 | 42 |
| EG002 | Adult Patients With Cardiac Arrhythmia Undergoing Pulsed Field Ablation | Safety was evaluated in adult patients diagnosed with cardiac arrhythmia, including patients with supraventricular tachycardia and ventricular tachycardia undergoing Pulsed Field Ablation procedure | 0 | 12 | 0 | 12 | 0 | 12 |
|
Not provided
Not provided
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| Title | Measurements |
|---|
|
| Device related |
|
| Procedure related |
|
| other |
|
| Serious Adverse Events |
|
| Serious adverse device effect (SADE) incidence |
|
| Serious unanticipated serious adverse device effect (USADE) incidence |
|
| Device deficiency incidence |
|
|
| Sensitivity |
|
|
|
Automated PVI Analyzer classification of PV isolation in SR by Radiofrequency procedure from EP procedure until study completion at discharge (an average of 24 hours), with sensitivity superior to 80%. A superiority Z-test for Sensitivity was performed. |
| Z-test |
| 0.32 |
Computed p values are the result of running a one sample z-test with a null hypothesis that sensitivity is below 80% and alternative hypothesis that sensitivity is at or above 80%. |
| Percentage (%) |
| 82 |
| 2-Sided |
| Superiority |
| Automated PVI Analyzer classification of PV isolation in SR by Cryo-balloon procedure from EP procedure until study completion at discharge (an average of 24 hours), with a specificity superior to 80%. A superiority Z-test for Specificity was performed. | Z-test | 0.66 | Computed p values are the result of running a one sample z-test with a null hypothesis that specificity is below 80%. | Percentage (%) | 79 | 2-Sided | Superiority |
| Automated PVI Analyzer classification of PV isolation in SR by Cryo-balloon procedure from EP procedure until study completion at discharge (an average of 24 hours), with a sensitivity superior to 80%. A superiority Z-test for Sensitivity was performed. | Z-test | 0.0008 | Computed p values are the result of running a one sample z-test with a null hypothesis that sensitivity is below 80% and alternative hypothesis that sensitivity is at or above 80%. | Percentage (%) | 92 | 2-Sided | Superiority |
| Sensitivity |
|
|
| The data analysis and processing were similar to those of the primary endpoint, but taking into consideration that subjects shall be in non-sinus rhythm during the duration of the EGM snippet. Apart from this, the processing was the same and the threshold was also defined as 50: values below 50 were classified as baseline, while values at or above 50 were considered as isolated veins. | Z-test | 0.0007 | The p values calculated are the result of running a one sample z-test with a null hypothesis that the sensitivity are below 80% and an alternative hypothesis that sensitivity is at or above 80%. | Percentage (%) | 100 | 2-Sided | Superiority |
|
| Sensitivity |
|
|